Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin [May 2016]

Product Code:
596200704
Publication Date:
April 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include the FDA’s approval of Celltrion’s Inflectra in April 2016, as well as the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) in respect of Samsung Bioepis’ Flixabi; the FDA’s approval of InDex Pharmaceuticals’ application for a Phase IIb study of Kappaproct (cobitolimod); as well as opinions on the Simponi (golimumab) Phase IV GO-COLITIS trial.

Key Questions Answered in this Update Bulletin:

  • How do gastroenterologists perceive anti-TNF biosimilars?
  • How will the US launch of Inflectra and the EU arrival of Flixabi impact the respective markets?
  • How clinically attractive is Kappaproct (cobitolimod)?
  • Will the Phase IV GO-COLITIS trial affect prescribing practice?
  • How will the availability of biosimilar adalimumab influence the UC market?



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved